The Czech Myeloma Group (CMG) was established in 1996. The main objective of the CMG is to organize and coordinate research and clinical activities in the Czech Republic in the area of multiple myeloma. It ensures that the best current standards of care for patients with multiple myeloma are met. Its clinical studies provide the Czech patients with multiple myeloma the access to the latest experimental treatments in the field.
As the activities spread out, The Czech Myeloma Group Foundation was established in 2001 to give support to patient related activities and promotions.
All activities of The CMG and of its Foundation are directed at improvements of the treatment of multiple myeloma in the Czech Republic. Also, both organizations aim to provide a relief from the many problems and conditions that limit the quality of life of patients suffering from multiple myeloma.
| A brief history of The CMG | |
| 1996 | CMG founded |
| 2001 | CMG Foundation established |
| 2003 | Cooperation with The International Myeloma Foundation (IMF) initiated |
| 2005 | Communication among countries of Central and Eastern Europe within the new multicenter clinical trial started |
| 2006 | Independent Patient organization established |
| 2006 | Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre founded |
| 2007 | CMG became a partner of The IMF |
The CMG is an association of physicians and other researchers with main interest in scientific investigation, diagnostics and therapy of multiple myeloma and monoclonal gammopathy.
Goals:
The CMG Foundation is an association of healthcare givers formed to meet the special needs of patients suffering from multiple myeloma, their families and friends.
Goals:
| A brief activities focused on physicians | |
| 1996 | The first multicentric study 4W started |
| 2002 | The second multicentric trial CMG 2002 initiated |
| 2003 | Guidelines for treatment of Multiple myeloma published |
| 2005 | Guidelines for treatment of Multiple myeloma upgraded |
| 2007 | Registry of monoclonal gammopathies opened |
| 2007 | Educational program CRAB (Toward a better quality of life through an earlier diagnosis) launched |
| A brief activities focused on the patients | |
| 2002 | Model project of waiting room in out-patient clinic finished |
| 2002 | HOT-LINE installed |
| 2002 | The benefit performances held regularly |
| 2003 | Patients brochures published regularly in association with The IMF |
| 2005 | The first Patient & Family Seminar held in Lednice |
| 2006 | Independent Patient organization established |
| 2006 | The second Patient & Family Seminar held in Podebrady |
| 2007 | The third Patient & Family Seminar held in Lednice |
| Treatments accessibility | |
| 1996 | Autologous transplantation implemented to the treatment regimen |
| 2002 | More than 80% of patients indicated for autologous transplantation benefit from this treatment |
| 2001 | Thalidomide introduced in the Czech Republic |
| 2004 | Thalidomide reimbursed for relapsed patients |
| 2004 | Bortezomib introduced in the Czech Republic through Velcade initiation programME |
| 2005 | Bortezomib reimbursed for relapsed patients |
| 2007 | Thalidomide reimbursed for newly diagnosed patients |
| 2007 | Lenalidomide introduced in the Czech Republic through LENALIDOMIDE NAMED PATIENT PROGRAMME |
The preclinical research was focused mainly on immunotherapy, development of anti-tumor vaccines respectively in the period 1998-2002. More complex research program, established in the year 2002, finally led to opening new Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre in Brno as the reference research centre of The Czech Myeloma Group. This centre works closely with academic field and participates in clinical activities of the Czech Myeloma Group which gives a great opportunity to promote research on multiple myeloma and monoclonal gammopathy. The centre connection with academic field and coordination with clinical activities of The Czech Myeloma Group gives a great opportunity to reinforce research of multiple myeloma and monoclonal gammopathy. The main research projects are focused on pharmocogenomics and proteomics.
| A brief preclinical research | |
| 1998 | Laboratory of hematology and experimental immunotherapy founded |
| 2003 | The first anti-myeloma vaccine applied |
| 2004 | Biological sample bank and databases opened |
| 2005 | Project Bank on a Cure - participation in the Czech Republic initiated |
| 2006 | Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre founded |
The clinical research is mainly directed at the autologous transplantation and the role of maintenance and/or consolidation therapy. It is also focused on the re-transplantation for relapsed patients and on the phase I / II studies using anti-tumor vaccines.
| A brief clinical research - trials | |
| Clinical trials conducted by the CMG | |
| 1996-2002 | 4W - maintenance th. after autologous transplantation in newly diagnosed pts. |
| 2002-2007 | CMG 2002 - maintenance or consolidation th. after autologous transplantation in newly diagnosed pts. |
| 1998 | T2 model - re-transplantation and experimental th. after transplantation |
| 2003 | Anti-myeloma vaccine (KLH-Id protein) |
| 2005 | Prognostic impact of genetic abnormalities in the area of new drugs |
| 2006 | Anti-myeloma vaccine (dendritic cells) |
CRAB - Toward a better quality of life through an earlier diagnosis
Program is focused on family physicians and key out-patients physicians responsible for recognizing the symptoms related to MM (specialists of rheumatology, neurology, orthopedic or nephrology).
Initiation: 2007
Duration: 2007-2011
Anticipated outcome:
Transfer of methods
Program is focused on the standardization of laboratory examination methods in multiple myeloma in Central and Eastern Europe (incl. Czech Republic, Slovakia, Poland and Hungary).
Guaranteed by Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre
Initiation: 2006
Outcome:
International workshops:
Project MGUS 2007 - "2000 data sets in 2 year"
Initiation: 2007
Data-info part: follow up steps
Targets:
Research part: utilization of substantive information from RMG register and evaluation of samples stored in MM bank from pts. with MGUS and MM.
Aims:
